# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Curis (NASDAQ:CRIS) reported quarterly losses of $(0.68) per share which beat the analyst consensus estimate of $(1.36) by 50 p...
Curis, Inc. ("Curis") (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an or...
HC Wainwright & Co. analyst Joseph Pantginis assumes Curis (NASDAQ:CRIS) with a Buy rating and announces Price Target of...